Phenazepam

Quick links to important sections

Phenazepam

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phenazepam

Quick Facts

Property Description
Active ingredient Phenazepam (Bromdihydrochlorphenylbenzodiazepine)
Form Tablets, Aqueous Solution for Injection
Pharmacological class Benzodiazepine (CNS Depressant)
Common use Reduction of anxiety, muscle tension, and neural overactivity
Origin Synthetic (Developed in the former Soviet Union)

What Type of Medicine is Phenazepam?

Phenazepam is a potent, synthetic compound classified as a Benzodiazepine derivative, specifically belonging to the 1,4-Benzodiazepine subclass. It functions as a Central Nervous System (CNS) depressant, meaning its primary function is to slow down activity in the brain and spinal cord. The active compound defines its identity and pharmacological profile. A distinguishing factor is its origin: it was first developed in the former Soviet Union, with its primary authorized use concentrated in the Russian Federation and CIS countries. It is characterized as an agent with notably high potency and a long duration of action compared to many related compounds.

Composition and Available Pharmaceutical Forms

The medication is a single-active-ingredient product featuring Phenazepam as the sole therapeutic compound. For clinical use, it is primarily available in two pharmaceutical forms: solid tablets intended for oral ingestion, and an aqueous solution prepared for controlled parenteral administration via injection. This dual availability, encompassing both tablet and injectable solution forms, offers clinical versatility. The drug is a prescription-only medication, reflecting its potent nature and the necessity for professional medical oversight.

General Purpose and High-Level Effects

Phenazepam is intended for use in clinical scenarios where the goal is a rapid reduction of profound psychological and physical tension. The drug achieves its therapeutic goal by functioning as a positive allosteric modulator of the GABA-A receptor complex, thereby strengthening the effects of the inhibitory neurotransmitter GABA.

By amplifying this natural calming signal, the medication helps to induce three core effects: a potent anxiolytic (anti-anxiety) effect, pronounced sedative-hypnotic qualities, and muscle-relaxant properties, which help restore inhibitory balance within the CNS. The medication is typically utilized in contexts such as managing severe, acute anxiety or addressing muscle tension associated with specific neurological conditions.

What side effects are possible with Phenazepam?

Possible Side Effects and Safety Information

The safety profile of Phenazepam, a potent Central Nervous System (CNS) depressant, is primarily structured around its sedative properties and the inherent risks associated with the benzodiazepine class. The classification of adverse reactions is based on official regulatory documentation.

Adverse Reaction Categories

The most frequently reported experiences are those related to Nervous System Disorders, which are typically classified as common. These include drowsiness, fatigue, sedation, dizziness, confusion, and ataxia (impaired coordination). Less frequent events may involve gastrointestinal issues or dermatological reactions like a rash.

Classification Examples of Officially Documented Effects
Common Drowsiness, Sedation, Ataxia, Confusion, Muscle Weakness, Slurred Speech
Rare Paradoxical Reactions (Agitation, Aggression, Hostility)

Serious Safety Considerations

A critical concern explicitly documented by regulatory authorities is the risk of physical dependence and addiction, particularly with prolonged use. Abrupt cessation may lead to a life-threatening acute withdrawal syndrome. The medication also carries a risk of Respiratory Depression, which is significantly enhanced when combined with other CNS depressants, such as alcohol or opioids. The label specifies that this combination poses an increased danger of severe sedation and coma.

Population-Specific Safety

Official labeling contains specific notes for vulnerable groups. Older adults are documented as being at a higher risk of experiencing pronounced sedation, confusion, and ataxia, which may increase the risk of falls. The medicine is contraindicated in patients with severe pre-existing conditions, including severe hepatic impairment and severe respiratory failure, due to the potential for exacerbated adverse effects.

Overdose and Emergency Response

The official regulatory profile for Phenazepam overdose is characterized by severe Central Nervous System (CNS) depression, reflecting the drug’s high potency. The documented clinical presentation includes a spectrum of effects, such as extreme drowsiness, confusion, impaired coordination (ataxia), and decreased reflexes, potentially progressing to slurred speech and retrograde amnesia. Life-threatening outcomes involve the Respiratory and Cardiovascular systems, specifically respiratory depression and hypotension, which can lead to coma and respiratory arrest. The risk of fatality is compounded when Phenazepam is co-ingested with other CNS depressants, such as alcohol.

Mandatory Emergency Response

Authorities mandate that individuals must seek immediate medical attention or call 911 (or equivalent services) if overdose is suspected. This is required due to the critical risk of life-threatening outcomes.

Management and Monitoring

The officially described management is supportive care, which may necessitate procedures like mechanical ventilation and airway control to address respiratory compromise. The benzodiazepine-specific antagonist, Flumazenil, is available for controlled administration by healthcare professionals for potential reversal. Post-event procedures require continuous cardiorespiratory monitoring. Population-specific notes indicate that ataxia is the most common clinical sign documented in pediatric patients.

Therapeutic Uses of Phenazepam

What Phenazepam Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for managing symptoms. Phenazepam is commonly used in conditions characterized by periods of heightened symptoms, with its therapeutic scope concentrated in CIS countries.

This medication is applied in addressing several distressing symptom patterns, including severe anxiety and neurotic distress, sleep disorders, acute seizure activity such as Status Epilepticus, Alcohol Withdrawal Syndrome, and symptomatic relief of muscle spasticity and motor agitation. It is commonly used when short-term symptomatic assistance is needed during acute episodes of emotional tension or physical discomfort.

In a clinical context:

“The medication supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

By assisting with symptom stabilization, it contributes to easing the overall symptom load and supports general well-being during symptomatic periods.

Quick Fact: Symptomatic Support Focus
Symptom Focus Profound emotional tension, severe anxiety, and involuntary muscle spasms.
Clinical Context Applied during phases of increased distress or discomfort (e.g., crisis intervention, preoperative care, acute withdrawal).
Primary Benefit Offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. As documented by international reviews of its therapeutic application

Eligibility and Restrictions for Use

Who Can and Cannot Use Phenazepam? (Eligibility Profile)

Phenazepam is a prescription medication whose use is strictly governed by official regulatory contraindications and limitations. Eligibility is determined by specific medical conditions, age, and physiological states, as defined in authorized government prescribing information.


Absolute Contraindications (Must Not Use)

Use is contraindicated for patients with:

  • Known hypersensitivity to Phenazepam or any benzodiazepine.
  • Severe hepatic insufficiency (liver failure).
  • Severe respiratory insufficiency or sleep apnea syndrome.
  • Myasthenia gravis.
  • Acute alcohol or CNS depressant intoxication.

Populations Requiring Restricted Use

Use is limited or requires special caution for certain groups:

  • Elderly or Debilitated Patients: Require a reduced starting dose due to increased sensitivity and risk of adverse effects.
  • Pregnancy and Lactation: Use is generally not recommended or should be avoided due to potential risks to the fetus or infant.
  • Children and Adolescents: Use is typically not established or restricted due to insufficient safety data.
  • History of Substance Abuse: Requires extreme caution due to the high risk of developing dependence.
  • Impaired Liver or Kidney Function (Non-Severe): Requires caution and monitoring; dose adjustment may be necessary.

What should I know about interactions with other medicines?

Phenazepam Interactions with other medicines and products

This section summarizes officially documented interaction information for Phenazepam, based on government regulatory sources and high-level safety warnings.

Documented Interaction Patterns

The primary interaction pattern for Phenazepam is pharmacodynamic potentiation due to its role as a potent Central Nervous System (CNS) depressant. This effect, documented across regulatory bodies, results in an additive increase in CNS inhibition when combined with other substances that also depress the CNS.

Interacting Product Category Officially Documented Interaction Severity Classification
Opioid Medicines Heightened risk of profound sedation, respiratory depression, coma, and death. High Risk
CNS Depressants (General) Potentiation of sedative effects and increased risk of respiratory compromise. Caution/Significant
Alcohol Absolute contraindication due to significantly enhanced risk of severe toxicity and death. Prohibited Combination

Interaction-Related Restrictions and Considerations

The most significant restriction is the explicit contraindication for co-administration with alcohol. Furthermore, the combination of Phenazepam with opioid medicines carries the highest level of regulatory caution, necessitating avoidance unless alternatives are inadequate.

Population-Specific Note: Official monographs indicate that elderly or debilitated patients are more susceptible to the severe sedative effects of these interactions, thus amplifying the overall risk of excessive sedation and falls.

Mechanism of Action

Phenazepam functions in the central nervous system as a positive allosteric modulator of the GABA A receptor complex. Its primary molecular target is the benzodiazepine binding site, located typically at the interface of the alpha and gamma subunits of the pentameric GABA A receptor. Phenazepam binding induces a conformational change in the receptor structure. This modification increases the apparent affinity of the GABA A receptor for its endogenous agonist, gamma-aminobutyric acid (GABA), and enhances the frequency of the chloride ion channel opening events when GABA is bound.

The resulting inward flux of chloride ions across the neuronal membrane causes hyperpolarization of the neuron, increasing the membrane potential's negativity. This makes the neuron less excitable and raises the threshold required for action potential generation. The downstream cascade results in a widespread inhibition of neurotransmission throughout the central nervous system. System-level physiological consequences include modulation of wakefulness, motor coordination, and neuronal excitability.

Dosage and Administration Information

Administration principles for Phenazepam involve specific protocols. The medication is supplied in different forms, including tablets for oral ingestion and an aqueous solution for controlled intramuscular (IM) or intravenous (IV) injection. Transdermal patches are also a recognized delivery system.

The standard administration pattern involves a time-limited course of treatment. The typical oral starting dose for adults is 0.5 mg, which is administered in divided doses throughout the day. The daily dosage is limited and typically does not exceed 10 mg.

Treatment is generally intended for short-term use, often not exceeding two weeks, although therapy may span up to a maximum of two months in certain clinical scenarios. Upon completion of the course, the dose is reduced gradually as a procedural step to conclude the administration and mitigate the risk of withdrawal. Additionally, special dosing precaution is utilized when the medicine is used in older adults and in individuals with hepatic or renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Phenazepam

Evidence for use in Reducing Anxiety, Neurotic Distress, and Emotional Tension

Research was studied for short-term use in conditions characterized by anxiety, emotional tension, and neurotic distress. Study populations included individuals with conditions such as psychopathological changes linked to ischemic heart disease. Comparative clinical studies, including randomized double-blind trials, were used to explore Phenazepam against other standard medications. These studies observed patterns related to the evaluation of emotional tension during the short observation periods.

However, the evidence largely derives from older studies conducted primarily within the Russian Federation and CIS countries. This means that a comprehensive body of contemporary, independent international Randomized Controlled Trials (RCTs) is lacking. Consequently, data for certain groups remain insufficient, and the long-term effects are not fully established beyond the initial weeks of treatment.

Evidence for use in Managing Sleep Disorders and Muscle Spasticity

Phenazepam was evaluated in patients experiencing sleep disturbances (insomnia) and for its application in conditions involving muscle stiffness and spasms (spasticity). Research explored its use in patients experiencing insomnia and examined short-term symptom changes. Study outcomes examined measures related to the duration of sleep. For conditions marked by functional limitations such as muscle spasticity, research examined its effects on symptoms of muscle spasticity and motor agitation. Outcomes examined included the degree of muscle spasticity reduction and measures related to motor agitation.

What is Still Uncertain About Phenazepam Research

A notable concern is the limited information for long-term outcomes across the studied uses, as follow-up durations were limited in the core studies. Furthermore, the research base is highly concentrated geographically, meaning comparative evidence is lacking from independent international trials that use globally standardized methodologies. Evidence quality varies across studies, and there is a noted scarcity of widely published contemporary literature for global scientific review.

Key Studies & References

  1. Phenazepam (Bromdihydrochlorphenylbenzodiazepine) - DEA Diversion Control Division Monograph

Frequently Asked Questions (FAQ)

Common questions about Phenazepam (FAQ)

Q: How does Phenazepam compare generally to other benzodiazepines?

Official technical documents describe Phenazepam as a highly potent compound compared to many other benzodiazepines. It also has a noticeably long duration of action. For example, official reports estimate its potency to be five to ten times higher than that of Diazepam.


Q: What is the usual duration of action for Phenazepam?

Phenazepam is known for its long duration of action. Official documents report that this extended effect is consistent with its elimination half-life of around 60 hours. This long half-life is the pharmacological basis for its prolonged duration of action.


Q: How is Phenazepam different from Diazepam in its general characteristics?

Phenazepam is structurally related to Diazepam but differs significantly in its strength and how long it lasts in the body. Technical descriptions indicate that Phenazepam has an estimated 5- to 10-fold higher potency than Diazepam. Furthermore, it has a relatively longer elimination half-life of around 60 hours, a factor which contributes to its prolonged overall effects.


Q: What kind of monitoring might be needed for someone taking Phenazepam?

Therapeutic drug monitoring (TDM) for Phenazepam and its active metabolite is a recognized analytical consideration in clinical management. This approach is relevant because of the drug’s long half-life and the way individual bodies process the medicine, which can vary significantly.


Q: Is Phenazepam a fast-acting or slow-acting medicine?

Official documents indicate that Phenazepam is not among the fastest-acting compounds in its class. Following oral administration (taking the tablets), the onset of the medicine's effects is generally described as taking approximately 2 to 3 hours to begin.


Q: Are there common household items or supplements that interact with Phenazepam?

Official safety warnings for the benzodiazepine class indicate caution regarding some herbal and dietary supplements. Supplements that also cause sedation, like Kava, Valerian, Hops, and St. John's Wort, may increase the risk of pronounced drowsiness. Grapefruit juice is also noted in class warnings as it can potentially affect the rate at which the body processes the medication.


Q: Why is careful monitoring emphasized with Phenazepam use?

Careful monitoring is stressed by regulatory bodies due to several factors, including the drug’s high potency and long half-life, which can prolong its effects. Furthermore, the documented risk of physical dependence and the serious dangers of respiratory depression—especially when combined with other substances—are the basis for emphasizing close medical monitoring.


Q: What is the legal status of Phenazepam in different countries?

Phenazepam is primarily used and prescribed in the Russian Federation and CIS countries where it is authorized. It is not approved by the U.S. Food and Drug Administration (FDA) in the United States. Due to its potential for abuse and dependence, the United Nations Expert Committee on Drug Dependence (ECDD) recommended its placement under international control in Schedule IV of the 1971 Convention on Psychotropic Substances.


Q: Do regulatory agencies classify Phenazepam as a controlled substance?

Yes, international regulatory bodies recognize Phenazepam as a substance requiring strict controls. The United Nations Expert Committee on Drug Dependence (ECDD) has recommended its placement under international control in Schedule IV of the 1971 Convention on Psychotropic Substances.


Q: Can Phenazepam cause issues with memory?

Adverse reaction reports associated with Phenazepam and the benzodiazepine class indicate the possibility of issues related to the nervous system. These can include feelings of confusion and amnesia (memory loss).


Q: Is it true that Phenazepam has a long half-life?

Yes, official documents report that Phenazepam has a relatively long elimination half-life of approximately 60 hours. This pharmacological property is why the drug remains active in the body for an extended period compared to many similar medicines.


Q: Is Phenazepam associated with tolerance developing over time?

Official technical reports note that, like other benzodiazepines, Phenazepam can lead to the development of tolerance. This means the body can adapt to the presence of the medication over time, which may result in a reduced response to the same amount.


Q: What does 'dependence' mean in the context of Phenazepam use?

Physical dependence is described as a normal physiological outcome where the body adapts to the regular presence of the medication. This adaptation means the body needs the drug to function normally, and abrupt cessation would result in withdrawal symptoms. Physical dependence is considered a distinct physiological state from addiction.


Q: Why do official documents mention 'paradoxical reactions' with Phenazepam?

Paradoxical reactions are mentioned in official safety documents because they are a known, though rare, possibility within the benzodiazepine class. These reactions involve unexpected changes in behavior, such as increased agitation or hostility, which are the opposite of the medicine's intended calming effects.


Q: What are the official warnings about driving or operating machinery while using Phenazepam?

Regulatory warnings for Central Nervous System (CNS) depressants emphasize that Phenazepam can cause side effects like drowsiness, dizziness, and impaired coordination (ataxia). Due to the potential for impaired mental and physical performance, the effects of the drug are the basis for official warnings regarding the operation of complex or heavy machinery, including driving.


Q: What is the importance of the drug's schedule classification?

The drug's classification as a controlled substance is important because it signifies that it is subject to strict international and national controls. These controls regulate its manufacture, distribution, and prescribing, primarily due to its established potential for abuse, dependence, and possible harm if misused.


Q: Does Phenazepam have any known metabolites that are active?

Yes, the body processes Phenazepam into other compounds called metabolites, and at least one of these is known to be active. This compound is called 3-Hydroxyphenazepam, and it also works by acting on the GABA A receptor, which contributes to the drug's effects.

How should Phenazepam be stored and disposed of?

Phenazepam is not approved by the U.S. FDA; therefore, storage requirements are based on official regulatory documents from authorizing national health agencies (e.g., Russian Federation's GRLS).

Labeled Storage Condition Official Regulatory Requirement
Temperature Store at a temperature not exceeding 25 C (room temperature).
Protection Must be protected from light and moisture and kept in the original primary packaging.
Safety Keep out of the sight and reach of children.

The official storage profile mandates maintaining stability by strictly observing the 25 C maximum and protecting the product from environmental factors. Unused or expired Phenazepam must be disposed of according to local regulations and must not be discarded in household trash or poured into wastewater. Disposal is generally required through licensed collection points or pharmacy take-back programs, aligning with pharmaceutical waste handling for potent substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Phenazepam found in:

A-Z Index: